According to the public account of “Xuanwu Hospital Neurosurgery”, on March 9, 2022, the neurosurgery stereotaxic and functional brain disease team led by Professor Zhao Guoguang, President of Xuanwu Hospital of Capital Medical University, and Professor Shan Yongzhi of Neurosurgery successfully formed a team. A patient with intractable epilepsy (bilateral temporal lobe epilepsy) underwent implantation of the closed-loop reactive neurostimulation system Epilcure™ registration clinical trial.
The operation went smoothly, and all the indicators of the intraoperative stimulator worked normally. The postoperative reconstruction showed that the electrode position was accurate and the EEG signal was clear.
The successful completion of this implantation operation marks the first patient enrollment in the Epilcure™ National Medical Products Administration (NMPA)-registered clinical trial led by Xuanwu Hospital.
According to reports, the patient is male, and was diagnosed with bilateral temporal lobe epilepsy after admission. This type of epilepsy is a relative contraindication to craniotomy, and traditional treatment is not effective in the case of uncontrollable drugs.
The closed-loop reactive neurostimulation system is an important application of “brain-computer interface” in the clinical field. This technology uses artificial intelligence chips to be implanted in the skull, intracranial electrodes are implanted into the brain, and the EEG rhythm is monitored day and night without interruption. The occurrence of epilepsy, that is, the activation of exogenous interference rhythms, directly blocking the formation of epilepsy in the epileptogenic foci, and accurately controlling the activity of the loop.
Surgery implants artificial intelligence chip in patient’s skull
This new technology has brought good news to patients with epilepsy in multifocal or functional areas. The foreign product was approved by the US FDA in 2013, but it has been used as a “neck-stuck” technology for long-term technical blockade and restrictions in my country.
The implantation of this system means that the “brain-computer interface” high-tech product with independent intellectual property rights has reached the final step before full-scale clinical use after the arduous efforts and research of the domestic clinical and basic research team.